HealthX Connect Osaka 2026

1 Jul 2026 | Osaka, Japan

Register
Register
Register

EXORPHIA, INC.

Company (SME/startup) / 中小企業・スタートアップ

exorphia.com/en/pipeline/Tokyo, Japan
8 profile visits

About

EXORPHIA is pioneering next-generation therapeutics based on extracellular vesicles (EVs) to deliver innovative medicines that surpass the limits of existing treatments.

Through proprietary technologies, we have established high-activity EVs (Prime-EV), engineered EVs that can be flexibly loaded with antigens or drugs (Engineered EV), and an Advanced CMC platform that ensures reproducibility—all underpinned by a robust patent portfolio.

Our lead pipeline comprises three pillars:

(1) an IVF adjunct for infertility treatment (commercial launch in Japan planned for 2027–2028)

(2) an anti-inflammatory/anti-fibrotic therapy targeting ARDS, IPF, and atopic dermatitis (EXP01; aiming for a disease-modifying profile)

(3) an intranasal EV vaccine (EXP03; applicable from infectious-disease prevention to autoimmunity and oncology).

Through these programs, we will deliver safe, minimally invasive, and highly effective new treatments to clinical practice, and ultimately establish EVs as a versatile DDS platform to set a new standard for refractory diseases and preventive medicine.

Business Domain / 分野

Healthcare / ヘルスケアPharmaceuticals / 医薬品

Business Type / 業種

R&D / 研究開発

Disease Area/疾患領域

Infectious diseases /感染症Immunology/免疫・炎症Dermatology and sensory system/皮膚・感覚器

Technologies / 技術

Drug delivery system(DDS) / ドラッグデリバリーシステム

Additional Information

Requested business parter / ご希望のビジネスパートナー 

Healthcare/ヘルスケアPharmaceuticals / 医薬品R&D/研究開発

Representatives

Head of Business Develpemt

EXORPHIA, INC.